Rivus Pharmaceuticals gathers $35m Series A

Rivus Pharmaceuticals Inc, a biopharmaceutical company focused on treating cardio-metabolic health, has closed $35 million in Series A financing.

Rivus Pharmaceuticals Inc, a biopharmaceutical company focused on treating cardio-metabolic health, has closed $35 million in Series A financing. The investors included Longitude Capital, Medicxi and RxCapital.

Source: Press Release